Back to Search
Start Over
Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease.
- Source :
-
Pharmacogenomics [Pharmacogenomics] 2016 Apr; Vol. 17 (5), pp. 481-8. Date of Electronic Publication: 2016 Mar 29. - Publication Year :
- 2016
-
Abstract
- Aim: Levodopa is first-line treatment of Parkinson's disease motor symptoms but, dose response is highly variable. Therefore, the aim of this study was to determine how much levodopa dose could be explained by biological, pharmacological and genetic factors.<br />Patients & Methods: A total of 224 Parkinson's disease patients were genotyped for SV2C and SLC6A3 polymorphisms by allelic discrimination assays. Comedication, demographic and clinical data were also assessed.<br />Results: All variables with p < 0.20 were included in a multiple regression analysis for dose prediction. The final model explained 23% of dose variation (F = 11.54; p < 0.000001).<br />Conclusion: Although a good prediction model was obtained, it still needs to be tested in an independent sample to be validated.
- Subjects :
- Adult
Aged
Aged, 80 and over
Antiparkinson Agents administration & dosage
Drug Therapy, Combination
Female
Humans
Levodopa administration & dosage
Male
Middle Aged
Parkinson Disease genetics
Parkinson Disease physiopathology
Polymorphism, Single Nucleotide
Sex Factors
Antiparkinson Agents therapeutic use
Levodopa therapeutic use
Membrane Glycoproteins genetics
Nerve Tissue Proteins genetics
Parkinson Disease drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1744-8042
- Volume :
- 17
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Pharmacogenomics
- Publication Type :
- Academic Journal
- Accession number :
- 27019953
- Full Text :
- https://doi.org/10.2217/pgs.15.183